Skip to main content
TMDX
NASDAQ Industrial Applications And Services

TransMedics Group Appoints New Chief Commercial Officer and General Counsel

Arie Shkolnikov · Analysis by Wiseek AI
More coverage: Medical Device Stocks · Healthcare
Sentiment info
Neutral
Importance info
7
Price
$130.37
Mkt Cap
$4.455B
52W Low
$62.073
52W High
$156
52W Position info
110% above low
Off High info
16% below high
Rel. Volume info
1.0× avg
Market data snapshot near publication time

TMDX has more than doubled off its 52-week low of $62.073.

Summary

TransMedics Group announced the appointment of Giovanni Cecere as Chief Commercial Officer and Matthew Forsyth as Senior Vice President, General Counsel & Corporate Secretary, effective February and March 2026, respectively.


Key Events · Executive and Board Changes · TMDX

  • New Chief Commercial Officer Appointed

    Giovanni Cecere has been appointed as the new Chief Commercial Officer, effective February 2, 2026.

  • Former CCO Transitions to SVP International

    Tamer Khayal, M.D., the outgoing Chief Commercial Officer, will transition to Senior Vice President of International, effective February 2, 2026.

  • New General Counsel Appointed

    Matthew Forsyth has been appointed as Senior Vice President, General Counsel & Corporate Secretary, effective March 9, 2026.

  • Former General Counsel Transitions with Agreement

    Anil Ranganath, the outgoing General Counsel, will transition to a non-executive employee position, then a non-employee consultant, with a separation date of June 7, 2026, under a detailed transition agreement.


Analysis · TMDX · Industrial Applications And Services

TransMedics Group announced significant leadership changes, appointing new Chief Commercial Officer and General Counsel. The transitions appear to be orderly, with the former CCO moving to a new senior role within the company and the former General Counsel having a structured transition and separation agreement. This suggests planned succession rather than abrupt departures, which mitigates potential negative market reaction.

How filings like this one have moved

In the 30 days to Sep 15, 2026, 29.9% of the 1678 measured filings Wiseek scored 7 moved their stock by 5% or more by the next session's close. The median move was -0.25%. These are measured outcomes after filings of this importance, not a forecast for this one.

Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset

At the time of this filing, TMDX was trading at $130.37 on NASDAQ in the Industrial Applications And Services sector, with a market capitalization of approximately $4.5B. The 52-week trading range was $62.07 to $156.00. This filing was assessed with neutral market sentiment and an importance score of 7 out of 10.

View Main SEC Filing

Price Chart

Share this article

Copied!

TMDX - Latest Insights

TMDX
Aug 04, 2026, 4:44 PM EDT
Source: Reuters
Importance Score:
8
Price at Filing: $88.04
Real-time Price: $87.00 info
Change: -$1.04 (-1%) info
Market Cap: $2.977B info
TMDX
Aug 04, 2026, 4:20 PM EDT
Source: Dow Jones Newswires
Importance Score:
7
Price at Filing: $88.50
Real-time Price: $87.00 info
Change: -$1.50 (-2%) info
Market Cap: $2.977B info
TMDX
Aug 04, 2026, 4:15 PM EDT
Filing Type: 10-Q
Importance Score:
8
Price at Filing: $88.00
Real-time Price: $87.00 info
Change: -$1.00 (-1%) info
Market Cap: $2.977B info
TMDX
Aug 04, 2026, 4:05 PM EDT
Filing Type: 8-K
Importance Score:
8
Price at Filing: $82.01
Real-time Price: $87.00 info
Change: +$4.99 (+6%) info
Market Cap: $2.977B info
TMDX
May 21, 2026, 4:15 PM EDT
Filing Type: 8-K
Importance Score:
8
Price at Filing: $68.85
Real-time Price: $87.00 info
Change: +$18.15 (+26%) info
Market Cap: $2.977B info